Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28477211 | 0.83 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL30106737 | 0.77 | ERN1 (0.57) | NFE2L2ALDH1A1ERN1GRIN2DGRIN3B | |
| SCHEMBL1695015 | 0.77 | ERN1 (0.57) | NFE2L2ALDH1A1ERN1GRIN2DGRIN3B | |
| SCHEMBL29620247 | 0.76 | NFE2L2 (0.44) | NFE2L2ALDH1A1ERN1GRIN2DGRIN3B | |
| SCHEMBL242300 | 0.76 | CD44 (0.42) | ALDH1A1 | |
| SCHEMBL466535 | 0.76 | NFE2L2 (0.44) | NFE2L2ALDH1A1ERN1GRIN2DGRIN3B | |
| SCHEMBL29906330 | 0.75 | — | — | |
| SCHEMBL50061 | 0.75 | — | — | |
| SCHEMBL16933848 | 0.74 | NFE2L2 (0.50) | NFE2L2ALDH1A1ERN1 | |
| SCHEMBL113475 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778347-B | Synthetic method of boron nitrogen benzocarbazole derivative | 九江善水科技股份有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-11149040-B2 | Fused triazole agonists of the APJ receptor | AMGEN INC. (US) | 2021-10-19 | — | — | US | disclosed |
| CN-112778347-A | Synthetic method of boron nitrogen benzocarbazole derivative | 九江善水科技股份有限公司 | 2021-05-11 | — | — | CN | disclosed |
| US-20200308189-A1 | FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-10189863-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-10189863-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| EP-3204388-B1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LTD (GB) | 2018-12-12 | — | — | EP | disclosed |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| EP-3204388-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | Pulmocide Limited (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055792-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055792-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2016-04-14 | — | — | WO | disclosed |
| EP-1066286-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308189-A1 | FUSED TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AP3M1, GPBAR1 | NFE2L2 3184/4885ALDH1A1 2156/4885ERN1 3974/4885 |
| US-10189863-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | AZI2, HRH4, ZC3HAV1 | NFE2L2 2123/4885ALDH1A1 1873/4885ERN1 3304/4885 |
| US-11149040-B2 | Fused triazole agonists of the APJ receptor | TBXA2R, AP3M1, GPBAR1 | NFE2L2 3184/4885ALDH1A1 2156/4885ERN1 3974/4885 |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | ZC3HAV1, DHX15, AZI2 | NFE2L2 2099/4885ALDH1A1 1756/4885ERN1 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.